

Tetraenylstannanes in the Synthesis of Retinoic Acid and Its Ring-Modified Analogues


Beatriz Domínguez, Beatriz Iglesias, and
Angel R. de Lera*

Departamento de Química Física y Química Orgánica,
Facultad de Ciencias, Universidad de Vigo,
36200 Vigo (Spain)


Received January 21, 1998

Retinoids (vitamin A and its structural and functional analogues) are currently the subject of intense biological interest stimulated by the discovery and characterization of retinoid receptors¹ and the subsequent consideration of retinoic acids as nonsteroidal small-molecule hormones. The retinoid families of nuclear proteins [RARs (retinoic acid receptors) and RXRs (retinoid X receptors)] comprising subtypes RAR α,β,γ and RXR α,β,γ act as ligand-inducible transcription factors in the proliferation and differentiation of mammalian cells. *trans*-Retinoic acid (**1a**) is the natural ligand for RAR, and its isomer 9-*cis*-retinoic acid (**2**) has high affinity for, and activates, both RAR and RXR.

The effects of retinoids on cell differentiation and biological proliferation have spurred the synthesis and biological evaluation of numerous retinoic acid analogues.² Since the subtypes within each receptor family, which are encoded by separate genes, show some differences in tissue distribution, synthetic retinoids selective for individual subtypes would be important tools for better delineation of the multiple effects of retinoids in mammalian cells.³



- 1a**, R₁ = R₂ = R₃ = Me
1b, R₁ = R₂ = Me, R₃ = H
1c, R₁ = H, R₂ = R₃ = Me
1d, R₁ = R₂ = H, R₃ = Me
1e, R₁ = H, R₂ = Me, R₃ = H
1f, R₁ = R₂ = R₃ = H



* To whom correspondence should be addressed, phone: (34) 86 812316, fax: (34) 86 812382, e-mail: qolera@uvigo.es.

(1) For reviews, see: (a) Evans, R. M. *Science* **1988**, *240*, 889. (b) Mangelsdorf, D. A.; Evans, R. M. *Cell* **1995**, *83*, 841. (c) Katzenellenbogen, J. A.; Katzenellenbogen, B. S. *Chem. Biol.* **1996**, *3*, 529.

(2) (a) Dawson, M. I.; Okamura, W. H., Eds. *Chemistry and Biology of Synthetic Retinoids*; CRC Press: Boca Raton, FL, 1990. (b) Rosen, J.; Day, A.; Jones, T. K.; Jones, E. T. T.; Nadzan, A. M.; Stein, R. B. *J. Med. Chem.* **1995**, *38*, 4855.

(3) For a recent review, see: Curley, R. W.; Robarge, M. J. *Curr. Med. Chem.* **1996**, *3*, 325.

In some of the most active known retinoids, the unstable polyolefinic chain of **1a** is stabilized by the inclusion of some of its double bonds in aromatic rings. However, our structure–activity studies have recently led us to investigate a synthetically more challenging series of ring-modified retinoic acid analogues (**1b–f**), all of them with the unaltered side-chain of **1a**.

Traditional routes to retinoids, based on olefin elongation procedures (Wittig, Horner–Wadsworth–Emmons, and Julia reactions),^{2a} are recently being replaced by more stereoselective approaches.^{4–6} Use of the Suzuki reaction⁵ for the synthesis of retinoic acid analogues with unmodified side chains is limited by the instability of the corresponding conjugated alkenylboronic acids. The popular Stille reaction⁶ is more versatile: alkenylstannanes remain unaltered upon treatment with a variety of reagents under a diversity of reaction conditions, and recent improvements⁷ using alternative catalysts, co-catalysts, and solvents can allow the use of reaction conditions that are considerably milder than those originally reported.⁶

Since we are interested in modifying only the cyclohexenyl ring of retinoic acid, we decided to use the polyenic functionalized stannane **5** (Scheme 1) as the common Stille coupling partner of vinyltriflates **8a–f** (which can be prepared regioselectively from the commercially available cyclohexanones **7^b**) in a new synthesis of retinoic acid (**1a**) and the ring-modified analogues **1b–f**. This paper reports our results.

Tetraenylstannane **5** was prepared in good yield and with excellent stereoselectivity by Horner–Wadsworth–Emmons condensation, at $-78\text{ }^{\circ}\text{C}$, of known stannane **3⁹** and the carbanion derived from the treatment of phosphonate **4¹⁰** with *n*-BuLi and 1,3-dimethyl-3,4,5,6-tetrahydro-2(1*H*)-pyrimidinone (DMPU) in THF at $0\text{ }^{\circ}\text{C}$ ¹¹ (Scheme 1). Treatment of 2,2,6-trimethylcyclohexanone (**7a**) with LDA at $-78\text{ }^{\circ}\text{C}$, followed by *N*-phenyltriflimide,

(4) (a) Negishi, E.; Owczarczyk, Z. *Tetrahedron Lett.* **1991**, *32*, 6683. (b) Bienayme, H.; Yezeguelian, C. *Tetrahedron* **1994**, *50*, 3389. (c) Trost, B. M.; Harms, A. E. *Tetrahedron Lett.* **1996**, *37*, 3971. (d) Trost, B. M.; Sorum, M. T.; Chan, C.; Harms, A. E.; Rühler, G. *J. Am. Chem. Soc.* **1997**, *119*, 698. (e) Lipshutz, B. H.; Lindsley, C. *J. Am. Chem. Soc.* **1997**, *119*, 4555.

(5) (a) de Lera, A. R.; Torrado, A.; Iglesias, B.; López, S. *Tetrahedron Lett.* **1992**, *33*, 6205. (b) Torrado, A.; Iglesias, B.; López, S.; de Lera, A. R. *Tetrahedron* **1995**, *51*, 2435. (c) Torrado, A.; López, S.; Alvarez, R.; de Lera, A. R. *Synthesis* **1995**, 285. (d) de Lera, A. R.; Iglesias, B.; Rodríguez, J.; Alvarez, S.; López, S.; Villanueva, X.; Padrós, E. *J. Am. Chem. Soc.* **1995**, *117*, 8220.

(6) (a) Stille, J. K. *Pure Appl. Chem.* **1985**, *57*, 1771. (b) Stille, J. K. *Angew. Chem., Int. Ed. Engl.* **1986**, *25*, 508. (c) Mitchell, T. N. *Synthesis* **1992**, 803. (d) Sato, T. In *Comprehensive Organometallic Chemistry II*; Abel, E. W., Stone, F. G. A., Wilkinson, G., Eds.; Elsevier: Oxford, 1995; Vol. 11, Chapter 8, pp 355–387.


(7) Farina, V. *Pure Appl. Chem.* **1996**, *68*, 73.

(8) Ritter, K. *Synthesis* **1993**, 735.


(9) Yokokawa, F.; Hamada, Y.; Shioiri, T. *Tetrahedron Lett.* **1993**, *34*, 6559.

(10) (a) Ahmad, I.; Gedye, R. N.; Nechvatel, A. *J. Chem. Soc. (C)* **1968**, 185. (b) Pattenden, G.; Weedon, B. C. L. *J. Chem. Soc. (C)* **1968**, 1984. (c) Bergdahl, M.; Hett, R.; Friebe, T.; Gangloff, A. R.; Iqbal, J.; Wu, Y.; Helquist, P. *Tetrahedron Lett.* **1993**, *34*, 7371. (d) Helquist, P.; Bergdahl, M.; Hett, R.; Gangloff, A. R.; Demillequand, M.; Cottard, M.; Mader, M. M.; Friebe, T. L.; Iqbal, J.; Wu, Y.; Åkermark, B.; Rein, T.; Kann, N. *Pure Appl. Chem.* **1994**, *66*, 2063. (e) Mata, E. G.; Thomas, E. J. *J. Chem. Perkin Trans. 1* **1995**, 785.

(11) Bennani, Y. L.; Boehm, M. F. *J. Org. Chem.* **1995**, *60*, 1195.

Scheme 1^a


- a, R₁ = R₂ = R₃ = Me
 b, R₁ = R₂ = Me, R₃ = H
 c, R₁ = H, R₂ = R₃ = Me
 d, R₁ = R₂ = H, R₃ = Me
 e, R₁ = H, R₂ = Me, R₃ = H
 f, R₁ = R₂ = R₃ = H



^a Reagents and conditions: (a) LDA, THF, -78 °C, 2 h; then *N*-phenyltriflimide, THF, 0 °C, 12 h. (b) *i*-Pr₂NH, MeMgBr; then *N*-phenyltriflimide, THF, 0 °C, 12 h. (c) *n*-BuLi, DMPU, THF, 0 °C, 20 min; then aldehyde **3**, -78 °C, 3 h. (d) DIBALH, THF, -78 °C, 30 min.

gave the corresponding triflate **8a**.¹² The same procedure was employed for the synthesis of triflates **8b**, **8c**,^{12b} **8e**,^{12b} and **8f**¹³ starting from the corresponding ketone precursors. Treatment of 2-methylcyclohexanone diisopropylamide at 0 °C, followed by treatment with *N*-phenyltriflimide, afforded **8d** as the only isolable regioisomer.¹⁴

Table 1 shows the results of preliminary studies of the coupling reaction affording the parent ethyl retinoate **9a**.¹⁵ Several recent modifications of the Stille protocol were examined. The catalyst system affording best conversion was Farina's "soft" palladium Pd₂(dba)₃ with AsPh₃ as ligand and *N*-methyl-2-pyrrolidinone (NMP) as solvent;¹⁶ the optimal proportions of catalyst and ligand were found to be 2.5% Pd₂(dba)₃ (5% Pd) and 20% AsPh₃ (entries 1 and 2). As in the intramolecular reactions reported by Piers, and in contrast to other intermolecular reactions, LiCl was not necessary for coupling **5** to **8a**.¹⁷ We tried using LiCl (3 equiv), with and without ligand (entries 3 and 4). However, since temperatures of 70 °C were required for appreciable coupling (Farina^{18a} too

Table 1. Optimization of Reaction Conditions for the Palladium-Catalyzed Cross-Coupling of Tetraenylstannane **5** and Vinyl Triflate **8a**

entry	8a : 5	solvent	cat. ^a	additive	<i>T</i> (°C)	<i>t</i> (h)	yield 9a ^b (%)	yield 10 ^c (%)
1	1.0:1.1	NMP	A	—	70	2	62	30 ^d
2	1.1:1.0	NMP	A	—	70	2	68	29
3	1.0:1.1	NMP	B	LiCl ^e	25	2.5	77 ^f	23
4	1.0:1.1	NMP	A	LiCl ^e	60	2.5	56 ^f	48
5	1.0:1.1	DMF/THF	C	—	80	3	<i>g</i>	<i>g</i>
6	1.1:1.0	NMP	A	BHT ^h	70	1	61	39
7	1.1:1.0	NMP	B	—	70	5	—	78
8	1.1:1.0	NMP	A	Cu ⁱ	70	1	<i>g</i>	58

^a A = 2.5 mol % Pd₂(dba)₃, 20 mol % AsPh₃; B = 2.5 mol % Pd₂(dba)₃; C = 5 mol % PdCl₂(CH₃CN)₂. ^b Yield based on starting triflate **8a**. ^c Yield based on starting stannane **5**. ^d The same ratio was obtained with five freeze-thaw deoxygenation cycles and slow addition of stannane **5** (ca. 2 h, syringe pump). ^e 3 equiv. ^f Mixture of isomers. ^g Decomposition. ^h 25 mol %. ⁱ 5 mol %.

found **8a** to react sluggishly with arylstannanes in the presence of AsPh₃, omitting AsPh₃ allowed room-temperature coupling, but the LiCl reduced the isomeric purity of the polyene products, and omitting both AsPh₃ and LiCl led to the homodimer **10** alone, with no **9a** (entry 7). An alternative palladium catalyst led to extensive decomposition (entry 5).

In all coupling reactions, substantial amounts of the red homodimer **10** were obtained through a competitive process that was only slightly depressed by using excess triflate (1.1:1, entry 2). Homocoupling of vinylstannanes (and even bromides) was first described by Stille,^{18b} and although Stille described it as insensitive to the presence or absence of oxygen,^{18c} Farina reported it to be due to an oxidative process, caused by oxygen in the medium,^{18a} that could be minimized by using both AsPh₃ and LiCl or by careful degassing. In this work, careful deoxygenation of reaction flasks and solvents (five freeze-thaw cycles) failed to reduce stannane homocoupling significantly, even if stannane was slowly added with a syringe pump as the reaction progressed.¹⁹ Nor did the presence of a radical scavenger (25 mol % 2,6-di-*tert*-butyl-4-methylphenol, BHT) either reduce homocoupling or improve product yield (entry 6). Rather, it seems that factors related to substrate reactivity favor the formation of **10** (see below).

Unlike Stille reactions with PPh₃ as palladium ligand, in which copper salts²⁰ seem to enhance efficiency by scavenging this ligand, reactions with low-donicity AsPh₃

(12) (a) Scott, W. J.; Crisp, G. T.; Stille, J. K. *J. Am. Chem. Soc.* **1984**, *106*, 4630. (b) Wulff, W. D.; Peterson, G. A.; Bauta, W. E.; Chan, K.-S.; Faron, K. L.; Gilbertson, S. R.; Kaesler, R. W.; Yang, D. C.; Murray, C. K. *J. Org. Chem.* **1986**, *51*, 279.

(13) (a) Stang, P. J.; Dueber, T. E. *Org. Synth.* **1974**, *54*, 79. (b) Stang, P. J.; Treptow, W. *Synthesis* **1980**, 283.

(14) Crisp, G. T.; Scott, W. J.; Stille, J. K. *J. Am. Chem. Soc.* **1984**, *106*, 7500.

(15) Trost, B. M.; Fortunak, J. M. D. *Tetrahedron Lett.* **1981**, *22*, 3459.

(16) Farina, V.; Krishnan, B. *J. Am. Chem. Soc.* **1991**, *113*, 9585.


(17) (a) Piers, E.; Friesen, R. W. *J. Org. Chem.* **1986**, *51*, 3405. (b) Piers, E.; Friesen, R. W.; Keay, B. A. *Tetrahedron* **1991**, *47*, 4555.

(18) (a) Farina, V.; Krishnan, B.; Marshall, D. R.; Roth, G. P. *J. Org. Chem.* **1993**, *58*, 5434. (b) Stille, J. K.; Groh, B. L. *J. Am. Chem. Soc.* **1987**, *109*, 813. (c) Scott, W. J.; Stille, J. K. *J. Am. Chem. Soc.* **1986**, *108*, 3033.

(19) Kang, S.-K.; Kim, J.-S.; Choi, S.-C. *J. Org. Chem.* **1997**, *62*, 4208.

(20) (a) Liebeskind, L. S.; Fengl, R. W. *J. Org. Chem.* **1990**, *55*, 5539. (b) Gómez-Bengoá, E.; Echavarren, A. M. *J. Org. Chem.* **1991**, *56*, 3947. (c) Tamayo, N.; Echavarren, A. M.; Paredes, M. C. *J. Org. Chem.* **1991**, *56*, 6488. (d) Saá, J. M.; Martorell, G. *J. Org. Chem.* **1993**, *58*, 1963. (e) Piers, E.; Wong, T. *J. Org. Chem.* **1993**, *58*, 3609. (f) Farina, V.; Kapadia, S.; Krishnan, B.; Wang, C.; Liebeskind, L. S. *J. Org. Chem.* **1994**, *59*, 5905. (g) Roth, G. P.; Farina, V.; Liebeskind, L. S.; Peña-Cabrera, E. *Tetrahedron Lett.* **1995**, *36*, 2191. (h) Takeda, T.; Kabasawa, Y.; Fujiwara, T. *Tetrahedron* **1995**, *51*, 2515.

Table 2. Generalized Palladium-Catalyzed Cross-Coupling of Tetraenylstannane 5 and Vinyl Triflates 8 for the Synthesis of Ring-Modified Retinoids 9



entry ^a	R ₁	R ₂	R ₃	T (°C)	t (h)	product	yield 9 ^b (%)	yield 10 ^c (%)
1	Me	Me	Me	70	2	9a	62	30
2	Me	Me	H	50	2	9b	82	22
3	H	Me	Me	50	2	9c	56 ^{d,e}	35
4	H	H	Me	50	3	9d	76	18
5	H	Me	H	25	1	9e	70	17
6	H	H	H	25	0.5	9f	92	—

^a Reactions were carried out with 2.5 mol % Pd₂(dba)₃, 20 mol % AsPh₃ and 1:1.1 triflate/stannane in NMP. ^b Yield based on starting triflate 8. ^c Yield based on starting stannane 5. ^d Mixture of isomers. ^e Lower temperatures also afforded mixtures of isomers, and longer reactions times were required.

as ligand have been reported to be enhanced by copper through the generation of an organocopper species⁷ which might accelerate the rate-limiting transmetalation step of the catalytic cycle. In this work, however, addition of 5 mol % copper iodide (entry 8) or excess CuCN^{4e} led to extensive decomposition.

Table 2 lists the results of applying the optimized reaction conditions (entry 1 of Table 1) to the remaining cyclohexenyl triflates, whose lesser steric hindrance of the reaction is reflected in the lower temperatures needed to achieve high conversion rates. In all but one case (entry 3) good to excellent yields of the desired ethyl retinoate analogues were obtained, and the yield of the undesired octaene 10 was reduced (to zero in the case of entry 6). Clearly the homocoupling is significant only when the reactivity of the triflate is low and requires more vigorous reaction conditions.


The coupling reaction of the 2,6-dimethyl triflate analogue 8c was less successful. Extensive isomerization of both the starting stannane and the retinoate product was observed even after short reaction times. Reverse-phase HPLC monitoring showed very rapid catalytic turnover and deactivation within 5–10 min, even at the lowest temperature inducing coupling. Treatment of triflate 8c under the standard reaction conditions at 40 °C with the more reactive alcoholic tetraenylstannane 6 (obtained by DIBALH reduction of ester 5, Scheme 1) afforded 1-demethylretinol (12) in excellent yield, but efficiency was lost during conversion of 12 to an alkyl ester: tetrapropylammonium prerruthenate (TPAP)/N-methylmorpholine N-oxide (NMO) oxidation²¹ of 12 to 1-demethylretinal (13),²² followed by treatment of 13 under Corey's conditions (MnO₂/KCN/MeOH),²³ afforded the methyl ester 14 in 33% isolated yield from 8c.

(21) (a) Griffith, W. P.; Ley, S. V.; Whitcombe, G. P.; White, A. D. *J. Chem. Soc. Chem. Commun.* **1987**, 1625. (b) Griffith, W. P.; Ley, S. V. *Aldrichim. Acta* **1990**, 23, 13.

(22) Courtin, J. M. L.; Verhagen, L.; Biesheuvel, P. L.; Lugtenburg, J.; van der Bend, R. L.; van Dam, K. *Rec. Trav. Chim. Pays-Bas* **1987**, 106, 112.

(23) Corey, E. J.; Gilman, N. W.; Ganem, B. E. *J. Am. Chem. Soc.* **1968**, 90, 5616.

Scheme 2^a



^a Reagents and conditions: (a) 2.5 mol % Pd₂(dba)₃, 20 mol % AsPh₃, NMP, 40 °C, 2 h. (b) TPAP, NMO, CH₂Cl₂, 0 to 25 °C, 2 h. (c) MnO₂, KCN, MeOH, 0 °C, 2 h. (d) 1:4:2 M aqueous KOH/EtOH, reflux, 10 min.

Finally, basic hydrolysis of ethyl retinoate (9a) and the analogues 9b–f afforded the corresponding acids 1a–f.

In conclusion, tetraenylstannanes 5 and 6 were prepared and used for retinoid synthesis. Although limited in scope, this study highlights the importance of steric effects due to the electrophile, which has hitherto largely been ignored in studies of Stille reactions of vinyl systems. The occurrence of homocoupling, probably due to the low reactivity of hindered triflates, can severely limit the usefulness of highly conjugated stannanes. Despite attempts to characterize intermediates by NMR, Farina^{18a} was unable to propose a detailed mechanism for the homocoupling process. We are currently examining this secondary reaction in more detail.

Experimental Section²⁴

General Experimental Procedures. Proton (¹H NMR) and carbon (¹³C NMR) magnetic resonance spectra were recorded in CDCl₃ or C₆D₆. The tin–proton and tin–carbon coupling constants (*J*_{Sn–H} and *J*_{Sn–C}) are given as an average of the ¹¹⁷Sn and ¹¹⁹Sn values. Infrared spectra (IR) were recorded in 0.1-mm path length sodium chloride cavity cells. High-resolution mass spectra (HRMS) data were recorded at an ionizing voltage of 70 eV.

Analytical thin-layer chromatography was performed on Merck silica gel plates with F-254 indicator. Visualization was accomplished by UV light, iodine, or a 15% ethanolic phosphomolybdic acid solution. Flash chromatography was performed using E. Merck silica gel 60 (230–400 mesh).

All reactions were performed under a dry argon atmosphere in oven- and/or flame-dried glassware. Transfer of anhydrous solvents or mixtures was accomplished with oven-dried syringes or cannula. Solvents and reagents were distilled before use: dichloromethane from calcium hydride, and tetrahydrofuran from sodium benzophenone ketyl. "Brine" refers to saturated aqueous solution of NaCl.

All reactions involving retinoids as final products or starting materials were performed under subdued red light.

6,6-Dimethyl-1-[(trifluoromethanesulfonyl)oxy]cyclohex-1-ene (8b). A solution of diisopropylamine (0.46 mL, 3.3 mmol) in THF (3.8 mL) was cooled to 0 °C and treated with *n*-BuLi (2.94 M in hexanes, 1.12 mL, 3.3 mmol). The mixture was stirred at this temperature for 30 min and then cooled to –78 °C. A solution of 2,2-dimethylcyclohexanone (7b, 0.38 g, 3.0 mmol) in THF (3.8 mL) was slowly added, and the reaction mixture was stirred at –78 °C for an additional 2 h. *N*-phenyltriflimide (1.15 g, 3.21 mmol) in THF (3.8 mL) was then added, and the mixture was allowed to warm to 0 °C and was stirred at this temperature for 12 h. The solvent was then

(24) The purity of all new compounds was judged by a combination of HPLC and ¹H and ¹³C NMR analysis before mass spectra were recorded and is indicated in the Supporting Information by copies of the ¹H NMR/¹³C NMR spectra of selected compounds.

removed in vacuo and the resulting residue was diluted with hexane and washed with 10% HCl. The aqueous layer was extracted with hexane, and the combined organic layers were washed with 10% HCl, 10% NaOH, and H₂O, dried (MgSO₄), and concentrated. The residue was distilled under vacuum (50 °C/0.1 mmHg) to obtain 0.56 g of **8b** (72%) as a colorless oil. ¹H NMR (400.13 MHz, C₆D₆) δ 5.66 (t, *J* = 4.1 Hz, 1H), 2.1–2.2 (m, 2H), 1.6–1.7 (m, 4H), 1.15 (s, 6H); ¹³C NMR (100.61 MHz, CDCl₃) δ 156.3, 118.8, 116.6, 39.5, 35.4, 26.7, 25.3, 18.9.

Ethyl (2*E*,4*E*,6*E*,8*E*)-3,7-Dimethyl-9-(tri-*n*-butylstannyl)nona-2,4,6,8-tetraenoate (5). A solution of diethyl 3-(ethoxycarbonyl)-2-methylprop-2-enylphosphonate **4** (1.07 g, 4.05 mmol) in THF (4 mL) was cooled to 0 °C and treated with DMPU (1 mL, 8.32 mmol) and *n*-BuLi (1.66 M in hexanes, 2.3 mL, 3.82 mmol). The mixture was stirred at this temperature for 20 min and then cooled to –78 °C. A solution of aldehyde **3⁹** (0.87 g, 2.25 mmol) in THF (4 mL) was slowly added, and the reaction mixture was stirred at –78 °C for 3 h. The mixture was allowed to warm to 0 °C to complete the reaction. Saturated aqueous NH₄Cl was added, and the reaction mixture was extracted with Et₂O. The combined organic layers were washed with H₂O and brine, dried (MgSO₄), and concentrated. The residue was purified by chromatography on silica gel (93:5:2 hexane/ethyl acetate/Et₃N) to afford 0.82 g of **5** (73%) as a yellow oil. IR (NaCl, cm⁻¹) ν 1713 (m); ¹H NMR (400.13 MHz, C₆D₆) δ 6.93 (dd, *J* = 19.2 Hz, ³*J*_{Sn-H} = 62.7 Hz, 1H), 6.89 (dd, *J* = 15.1, 11.4 Hz, 1H), 6.61 (dd, *J* = 19.2 Hz, ²*J*_{Sn-H} = 97.7 Hz, 1H), 6.18 (d, *J* = 15.1 Hz, 1H), 6.13 (d, *J* = 11.4 Hz, 1H), 5.98 (s, 1H), 4.11 (q, *J* = 7.1 Hz, 2H), 2.46 (s, 3H), 1.82 (s, 3H), 1.6–1.7 (m, 6H), 1.4–1.5 (m, 6H, 3 × CH₂), 1.0–1.1 (m, 9H), 0.99 (t, *J* = 7.3 Hz, 9H); ¹H NMR (400.13 MHz, CDCl₃) δ 6.98 (dd, *J* = 15.0, 11.4 Hz, 1H), 6.63 (d, *J* = 19.2 Hz, ³*J*_{Sn-H} = 61.4 Hz, 1H), 6.43 (d, *J* = 19.2 Hz, ²*J*_{Sn-H} = 63.6 Hz, 1H), 6.32 (d, *J* = 15.0 Hz, 1H), 6.17 (d, *J* = 11.4 Hz, 1H), 5.78 (s, 1H), 4.17 (q, *J* = 7.1 Hz, 2H), 2.36 (s, 3H), 1.95 (s, 3H), 1.5–1.6 (m, 6H), 1.2–1.4 (m, 9H), 0.8–1.0 (m, 15H); ¹³C NMR (100.61 MHz, CDCl₃) δ 167.1, 152.5, 150.1 (⁵*J*_{Sn-C} = 10.4 Hz), 140.0, 136.0, 131.2 (¹*J*_{Sn-C} = 213.9 Hz), 131.0, 130.4, 118.9, 59.7, 29.1 (³*J*_{Sn-C} = 20.4 Hz), 27.3 (²*J*_{Sn-C} = 54.0 Hz), 14.7, 13.8, 13.7, 12.4, 9.53 (¹*J*_{Sn-C} = 336.5 Hz). HRMS *m/z* (M⁺) calcd for C₂₁H₃₅O₂¹¹⁸Sn 437.1653, found 437.1666.

Ethyl Retinoate (9a). General Procedure for Stille Reactions. A solution of Pd₂(dba)₃ (3.4 mg, 0.004 mmol) in NMP (1.4 mL) was treated with AsPh₃ (9 mg, 0.029 mmol) and, after 5 min, with a solution of triflate **8a** (40 mg, 0.147 mmol) in NMP (0.2 mL). After stirring for 10 min, a solution of stannane **5** (80 mg, 0.161 mmol) in NMP (0.2 mL) was added. The resulting solution was stirred at 70 °C for 2 h. After cooling, saturated aqueous KF solution (2 mL) was added, and the mixture was stirred for 30 min and extracted with Et₂O. The combined organic extracts were washed with H₂O and saturated aqueous KF solution, dried over MgSO₄, and concentrated to dryness. The residue was purified by chromatography (SiO₂, 98:2 hexane/ethyl acetate) to afford 30 mg (62%) of **9a**¹⁵ as a yellow oil and 10 mg (30%) of diethyl (2*E*,4*E*,6*E*,8*E*,10*E*,12*E*,14*E*,16*E*)-3,7,12,16-tetramethyloctadeca-2,4,6,8,10,12,14,16-octaene-1,18-dioate (**10**) as a red solid (mp: 150–158 °C). Data for **9a**: ¹H NMR (400.13 MHz, CDCl₃) δ 7.00 (dd, *J* = 15.0, 11.2 Hz, 1H), 6.29 (d, *J* = 15.0 Hz, 1H), 6.28 (d, *J* = 16.1 Hz, 1H), 6.15 (d, *J* = 11.2 Hz, 1H), 6.14 (d, *J* = 16.1 Hz, 1H), 5.78 (s, 1H), 4.17 (q, *J* = 7.1 Hz, 2H), 2.36 (d, *J* = 1.0 Hz, 3H), 2.0–2.1 (m, 2H), 2.00 (s, 3H), 1.72 (s, 3H), 1.4–1.6 (m, 4H), 1.29 (t, *J* = 7.1 Hz, 3H), 1.03 (s, 6H); ¹³C NMR (100.61 MHz, CDCl₃) δ 167.2, 152.8, 139.5, 137.6, 137.2, 135.1, 130.9, 130.0, 129.4, 128.5, 118.5, 59.7, 39.4, 34.2, 33.0, 28.9, 21.8, 19.1, 14.3, 13.7, 12.9. Data for **10**: IR (NaCl, cm⁻¹) ν 1698 (s), 1574 (m), 1150 (s); ¹H NMR (400.13 MHz, CDCl₃) δ 6.98 (dd, *J* = 15.0, 11.5 Hz, 2H), 6.4–6.5 (m, 4H), 6.33 (d, *J* = 15.1 Hz, 2H), 6.24 (d, *J* = 11.5 Hz, 2H), 5.80 (s, 2H), 4.18 (q, *J* = 7.1 Hz, 4H), 2.36 (s, 6H), 2.00 (s, 6H), 1.30 (t, *J* = 7.1 Hz, 6H); ¹³C NMR (100.61 MHz, CDCl₃) δ 167.6, 152.9, 139.6, 138.2, 136.6, 132.2, 131.1, 130.9, 119.6, 60.2, 14.8, 14.2, 13.4; HRMS *m/z* (M⁺) calcd for C₂₆H₃₄O₄ 410.2457, found 410.2463.

Ethyl 5-Demethylretinoate (9b). In accordance with the general procedure described above, a mixture of Pd₂(dba)₃ (5 mg, 0.005 mmol), AsPh₃ (13.5 mg, 0.044 mmol), triflate **8b** (57 mg, 0.22 mmol), and stannane **5** (120 mg, 0.24 mmol) in NMP (3.3 mL) was stirred at 50 °C for 2 h. The residue was purified by chromatography (SiO₂, 98:2 hexane/ethyl acetate) to afford 57 mg (82%) of **9b**²⁵ as a yellow oil and 11 mg (22%) of **10**.

Ethyl 1,1-Didemethylretinoate (9d). In accordance with the general procedure described above, a mixture of Pd₂(dba)₃ (6.9 mg, 0.0075 mmol), AsPh₃ (18.4 mg, 0.06 mmol), triflate **8d** (67 mg, 0.3 mmol), and stannane **5** (163 mg, 0.33 mmol) in NMP (4.4 mL) was stirred at 50 °C for 3 h. The residue was purified by chromatography (SiO₂, 98:2 hexane/ethyl acetate) to afford 68 mg (76%) of **9d**²⁵ as a yellow oil and 12 mg (18%) of **10**.

Ethyl 1,5-Didemethylretinoate (9e). In accordance with the general procedure described above, a mixture of Pd₂(dba)₃ (5.7 mg, 0.006 mmol), AsPh₃ (15.3 mg, 0.05 mmol), triflate **8e** (61 mg, 0.25 mmol), and stannane **5** (136 mg, 0.275 mmol) in NMP (3.3 mL) was stirred at room temperature for 1 h. The residue was purified by chromatography (SiO₂, 98:2 hexane/ethyl acetate) to afford 52 mg (70%) of **9e**²⁵ as a yellow oil and 10 mg (17%) of **10**.

Ethyl 1,1,5-Tridemethylretinoate (9f). In accordance with the general procedure described above, a mixture of Pd₂(dba)₃ (3.6 mg, 0.004 mmol), AsPh₃ (9.6 mg, 0.031 mmol), triflate **8f** (36 mg, 0.156 mmol), and stannane **5** (85 mg, 0.172 mmol) in NMP (2.3 mL) was stirred at room temperature for 30 min. The residue was purified by chromatography (SiO₂, 98:2 hexane/ethyl acetate) to afford 41 mg (92%) of **9f**²⁵ as a yellow oil.

Retinoic Acid (1a). General Procedure for Ester Hydrolysis. A solution of ethyl retinoate (**9a**; 20 mg, 0.061 mmol) in 1.9 mL of a 1:4 mixture of 2 M aqueous KOH and ethanol was refluxed for 10 min. The solution was cooled to room temperature and diluted with Et₂O (5 mL) and brine (5 mL). The organic layer was washed with H₂O, and the combined aqueous layers were acidified with 5% HCl to give a solution which was extracted with Et₂O. The combined organic extracts were washed with H₂O and brine and then dried (MgSO₄) and concentrated. The residue was purified on silica gel (95:5 CH₂Cl₂/MeOH) to afford 13 mg of **1a** (71%) as a yellow solid (mp 178–180 °C, EtOH). Physical and spectroscopic data matched those of commercially available retinoic acid.

5-Demethylretinoic Acid (1b). Application of the general procedure for ester hydrolysis to ethyl 5-demethylretinoate (**9b**) afforded, after chromatography on silica gel (95:5 CH₂Cl₂/MeOH), an 83% yield of 5-demethylretinoic acid (**1b**) as a yellow solid (mp 83–85 °C, EtOH).²⁵

1,1-Didemethylretinoic Acid (1d). Application of the general procedure for ester hydrolysis to ethyl 1,1-didemethylretinoate (**9d**) afforded, after chromatography on silica gel (95:5 CH₂Cl₂/MeOH), a 92% yield of 1,1-didemethylretinoic acid (**1d**) as a yellow solid (mp 211–213 °C, EtOH).²⁵

1,5-Didemethylretinoic Acid (1e). Application of the general procedure for ester hydrolysis to ethyl 1,5-didemethylretinoate (**9e**) afforded, after chromatography on silica gel (95:5 CH₂Cl₂/MeOH), a 66% yield of 1,5-didemethylretinoic acid (**1e**) as a yellow solid (mp 170–172 °C, EtOH).²⁵

1,1,5-Tridemethylretinoic Acid (1f). Application of the general procedure for ester hydrolysis to ethyl 1,1,5-tridemethylretinoate (**9f**) afforded, after chromatography on silica gel (95:5 CH₂Cl₂/MeOH), a 75% yield of 1,1,5-tridemethylretinoic acid (**1f**) (mp 173–175 °C, EtOH).²⁵

(2*E*,4*E*,6*E*,8*E*)-3,7-Dimethyl-9-(tri-*n*-butylstannyl)nona-2,4,6,8-tetraen-1-ol (6). A cooled (–78 °C) solution of tetraenylstannane **5** (0.25 g, 0.5 mmol) in THF (1.7 mL) was treated with DIBALH (1 M, 1 mL, 1 mmol) and stirred at –78 °C for 1 h. The reaction was quenched with a 2:3 MeOH/Et₂O mixture (2 mL) and allowed to reach room temperature. H₂O was added, and the mixture was extracted with Et₂O. The

combined organic extracts were washed with 10% NH₄Cl and brine, dried (MgSO₄), and concentrated to yield 0.16 g of **6** (72%) as a yellow oil which was used in the next step without further purification. IR (NaCl, cm⁻¹) ν 3500–3100 (br); ¹H NMR (400.13 MHz, C₆D₆) δ 6.95 (dd, J = 19.2 Hz, ³ $J_{\text{Sn-H}}$ = 64.1 Hz, 1H), 6.62 (dd, J = 15.1, 11.3 Hz, 1H), 6.50 (dd, J = 19.2 Hz, ² $J_{\text{Sn-H}}$ = 69.0 Hz, 1H), 6.2–6.3 (m, 2H), 5.59 (t, J = 6.6 Hz, 1H), 4.01 (br, 2H), 1.89 (s, 3H), 1.65 (quintet, J = 7.3 Hz, 6H), 1.59 (s, 3H), 1.40 (sextet, J = 7.3 Hz, 6H), 1.05 (t, J = 7.3 Hz, 6H), 0.94 (t, J = 7.3 Hz, 9H); ¹³C NMR (100.61 MHz, C₆D₆) δ 151.7 (⁴ $J_{\text{Sn-C}}$ = 10.2 Hz), 138.5, 136.8 (³ $J_{\text{Sn-C}}$ = 66.1 Hz), 135.9, 132.6, 132.5, 127.8, 125.1, 59.5, 29.7 (³ $J_{\text{Sn-C}}$ = 20.4 Hz), 27.9 (² $J_{\text{Sn-C}}$ = 54.0 Hz), 14.1, 12.6, 12.4, 10.0 (¹ $J_{\text{Sn-C}}$ = 334.2 Hz).

1-Demethylretinol (12). The general procedure for Stille reactions coupled triflate **8c** (35 mg, 0.15 mmol) and stannane **6** (82 mg, 0.165 mmol) after the reaction mixture was stirred at 40 °C for 2 h. The residue was purified by chromatography (silica, 80:18:2 hexane/ethyl acetate/Et₃N) to afford 42 mg (98%) of **12** as a yellow oil, which was immediately used in the next reaction (samples stored after their preparation underwent extensive decomposition).

1-Demethylretinal (13). To a solution of the alcohol **12** (88 mg, 0.323 mmol) in CH₂Cl₂ (4 mL) were added 4 Å molecular sieves and NMO (76 mg, 0.647 mmol). After stirring for 10 min and cooling to 0 °C, TPAP (5.7 mg, 0.016 mmol) was added and the mixture was stirred for 1 h at 0 °C, allowed to reach room temperature, stirred for an additional 1 h, diluted with CH₂Cl₂, filtered, and washed with saturated aqueous Na₂SO₃, brine, and saturated aqueous CuSO₄. The organic layer was dried over MgSO₄, filtered, and concentrated. The residue was purified by chromatography (silica, 93:5:2 hexane/ethyl acetate/Et₃N) to afford 41 mg (47%) of **13** as a yellow oil.²² IR (NaCl, cm⁻¹) ν 1657 (s); ¹H NMR (400.13 MHz, C₆D₆) δ 10.02 (d, J = 7.9 Hz, 1H), 6.86 (dd, J = 15.0, 11.4 Hz, 1H), 6.81 (d, J = 15.0 Hz, 1H), 6.41 (d, J = 15.0 Hz, 1H), 6.08 (d, J = 11.4 Hz, 1H), 6.07 (d, J = 15.0 Hz, 1H), 6.00 (d, J = 7.9 Hz, 1H), 2.70 (br, 1H), 1.8–2.0 (m, 2H), 1.82 (s, 3H), 1.73 (s, 3H), 1.68 (s, 3H), 1.4–1.7 (m, 4H), 1.17 (d, J = 7.0 Hz, 3H); ¹³C NMR (100.61 MHz, C₆D₆) δ 188.9, 153.7, 141.6, 135.5, 135.0, 134.5, 132.2, 131.0, 130.0, 128.8, 128.7, 34.0, 30.6, 28.6, 20.9, 20.1, 18.4, 13.4, 12.9; HRMS m/z (M⁺) calcd for C₁₉H₂₆O 270.1984, found 270.1986.

Methyl 1-Demethylretinoate (14). To a cooled (0 °C) solution of aldehyde **13** (40 mg, 0.148 mmol) in MeOH (1 mL) was added a mixture of KCN (48 mg, 0.741 mmol) and MnO₂ (257 mg, 2.96 mmol). After being stirred at 0 °C for 2 h, the mixture was filtered, diluted with Et₂O, and washed with brine. The residue was purified on silica gel (98:2 hexane/ethyl acetate) to afford 32 mg (72%) of **14** as a yellow oil. IR (NaCl, cm⁻¹) ν 1713 (m); ¹H NMR (400.13 MHz, CDCl₃) δ 7.02 (dd, J = 15.0, 11.4 Hz, 1H), 6.73 (d, J = 15.9 Hz, 1H), 6.30 (d, J = 15.9 Hz, 1H), 6.29 (d, J = 15.0 Hz, 1H), 6.22 (d, J = 11.4 Hz, 1H), 5.78 (s, 1H), 3.72 (s, 3H), 2.67 (br, 1H), 2.37 (s, 3H), 2.0–2.3 (m, 2H), 2.02 (s, 3H), 1.82 (s, 3H), 1.6–1.8 (m, 4H), 1.08 (d, J = 7.0 Hz, 3H); ¹³C NMR (100.61 MHz, CDCl₃) δ 167.6, 153.1, 140.3, 135.0, 134.7, 133.5, 131.2, 130.1, 129.8, 127.5, 117.8, 50.9, 33.4, 29.9, 27.7, 20.2, 19.7, 17.6, 13.8, 13.0; HRMS m/z (M⁺) calcd for C₂₀H₂₈O₂ 300.2089, found 300.2085.

1-Demethylretinoic Acid (1c). Application of the general procedure for ester hydrolysis to methyl 1-demethylretinoate (**14**) afforded, after chromatography on silica gel (95:5 CH₂-Cl₂/MeOH), a 78% yield of 1-demethylretinoic acid (**1c**) as a yellow solid (mp 187–190 °C, EtOH). IR (NaCl, cm⁻¹) ν 3600–3200 (br), 1679 (s); ¹H NMR (400.13 MHz, CDCl₃) δ 7.06 (dd, J = 15.0, 11.5 Hz, 1H), 6.75 (d, J = 16.0 Hz, 1H), 6.32 (d, J = 15.0 Hz, 1H), 6.31 (d, J = 16.0 Hz, 1H), 6.22 (d, J = 11.5 Hz, 1H), 5.80 (s, 1H), 2.68 (br, 1H), 2.38 (s, 3H), 2.0–2.2 (m, 2H), 2.04 (s, 3H), 1.83 (s, 3H), 1.5–1.8 (m, 4H), 1.08 (d, 3H, J = 7.0 Hz); ¹³C NMR (100.61 MHz, CDCl₃) δ 172.3, 155.8, 141.4, 135.7, 135.0, 133.9, 132.4, 130.5, 130.2, 128.2, 117.8, 33.9, 30.3, 28.2, 20.6, 20.2, 18.0, 14.4, 13.5; HRMS m/z (M⁺) calcd for C₁₉H₂₆O₂ 286.1933, found 286.1932.

Acknowledgment. We thank FIS (Contract 95/1534, which also supported Dr. Iglesias) and the Xunta de Galicia (grant XUGA30106B97) for financial support.

Supporting Information Available: Characterization data for compounds **9b**, **9d–f**, and **1d–f**, and copies of ¹H/¹³C NMR spectra of selected compounds described in the text (38 pages). This material is contained in libraries on microfiche, immediately follows this article in the microfilm version of the journal, and can be ordered from the ACS; see any current masthead page for ordering information.

JO980097W